CRISPR systems with engineered dual guide nucleic acids
The present invention relates to an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system comprising engineered dual guide nucleic acids (e.g., RNAs) capable of activating a CRISPR-Associated (Cas) nuclease, such as a type V-A Cas nuclease. Also provided are methods of targeting, editing, and/or modifying a nucleic acid using the engineered CRISPR system, and compositions and cells comprising the engineered CRISPR system.
1 . An engineered, non-naturally occurring system comprising:
(a) a targeter nucleic acid comprising, from 5′ to 3′:
(i) a targeter stem sequence; and
(ii) a spacer sequence designed to hybridize with a target nucleotide sequence; and
(b) a modulator nucleic acid comprising a modulator stem sequence complementary to the targeter stem sequence,
wherein the targeter nucleic acid and the modulator nucleic acid are separate nucleic acids, wherein a loop structure between the modulator stem sequence and the targeter stem sequence is absent, and wherein a complex comprising the targeter nucleic acid and the modulator nucleic acid is capable of activating a CRISPR Associated (Cas) nuclease that, in a naturally occurring system, is activated by a single crRNA in the absence of a tracrRNA, wherein the Cas nuclease comprises a Type V-A Cas nuclease; and
(c) the Type V-A Cas nuclease,
wherein the Type V-A Cas nuclease is an engineered Cas protein comprising one or more nuclear localization signal (NLS) motifs.
2 . The engineered, non-naturally occurring system of claim 1 wherein the targeter stem sequence and the modulator stem sequence are each 4-10 nucleotides in length.
3 . The engineered, non-naturally occurring system of claim 1 wherein the spacer sequence is 18 nucleotides in length or shorter.
4 . The engineered, non-naturally occurring system of claim 1 wherein the targeter nucleic acid comprises, from 5′ to 3′, the targeter stem sequence, the spacer sequence, and an additional nucleotide sequence.
5 . The engineered, non-naturally occurring system of claim 1 wherein the targeter nucleic acid, the modulator nucleic acid, or both, comprises a ribonucleic acid (RNA).
6 . The engineered, non-naturally occurring system of claim 5 wherein the targeter nucleic acid, the modulator nucleic acid, or both, comprises a chemically modified RNA.
7 . The engineered, non-naturally occurring system of claim 6 wherein the chemical modification is present in one or more nucleotides at the 3′ end of the targeter nucleic acid, in one or more nucleotides at the 5′ end of the modulator nucleic acid, or both.
8 . The engineered, non-naturally occurring system of claim 7 wherein the chemical modification is selected from the group consisting of 2′-O-methyl, 2′-fluoro, 2′-O-methoxyethyl, phosphorothioate, phosphorodithioate, pseudouridine, and any combinations thereof.
9 . The engineered, non-naturally occurring system of claim 1 wherein the modulator nucleic acid further comprises an additional nucleotide sequence positioned 5′ to the modulator stem sequence, and 4-50 nucleotides in length.
10 . The engineered, non-naturally occurring system of claim 9 wherein the additional nucleotide sequence comprises a donor template-recruiting sequence capable of hybridizing with a donor template.
11 . The engineered, non-naturally occurring system of claim 10 further comprising the donor template.
12 . The engineered, non-naturally occurring system of claim 1 wherein the targeter nucleic acid and the modulator nucleic acid are not covalently linked.
13 . The engineered, non-naturally occurring system of claim 1 wherein the Cas nuclease comprises an amino acid sequence at least 80% identical to SEQ ID NO: 1.
14 . The engineered, non-naturally occurring system of claim 1 wherein the Cas nuclease comprises an amino acid sequence at least 95% identical to SEQ ID NO: 1.
15 . The engineered, non-naturally occurring system of claim 1 wherein the targeter nucleic acid, the modulator nucleic acid, and the Cas nuclease are present in a ribonucleoprotein (RNP) complex.
16 . A CRISPR expression system comprising
(a) a nucleic acid comprising a first regulatory element operably linked to a nucleotide sequence encoding a targeter nucleic acid comprising, from 5′ to 3′:
(i) a targeter stem sequence; and
(ii) a spacer sequence designed to hybridize with a target nucleotide sequence;
(b) a nucleic acid comprising a second regulatory element operably linked to a nucleotide sequence encoding a modulator nucleic acid comprising a modulator stem sequence complementary to the targeter stem sequence,
wherein the targeter nucleic acid and the modulator nucleic acid are expressed as separate nucleic acids, wherein a loop structure between the modulator stem sequence and the targeter stem sequence is absent, and wherein a complex comprising the targeter nucleic acid and the modulator nucleic acid is capable of activating a Cas nuclease that, in a naturally occurring system, is activated by a single crRNA in the absence of a tracrRNA, wherein the Cas nuclease comprises a Type V-A nuclease; and
(c) a nucleic acid comprising a third regulatory element operably linked to a nucleotide sequence encoding a Type V-A Cas nuclease.
17 . The expression system of claim 16 wherein one or more of the nucleic acids is codon optimized for expression in a prokaryotic cell.
18 . The expression system of claim 16 wherein one or more of the nucleic acids is codon optimized for expression in E. coli.
19 . The expression system of claim 16 wherein one or more of the nucleic acids is codon optimized for expression in a eukaryotic cell.
20 . A method of cleaving a target DNA having a target nucleotide sequence, the method comprising contacting the target DNA with an engineered, non-naturally occurring system comprising
(a) a targeter nucleic acid comprising, from 5′ to 3′:
(i) a targeter stem sequence; and
(ii) a spacer sequence designed to hybridize with the target nucleotide sequence; and
(b) a modulator nucleic acid comprising a modulator stem sequence complementary to the targeter stem sequence,
wherein the targeter nucleic acid and the modulator nucleic acid are separate nucleic acids, wherein a loop structure between the modulator stem sequence and the targeter stem sequence is absent, and wherein a complex comprising the targeter nucleic acid and the modulator nucleic acid is capable of activating a CRISPR Associated (Cas) nuclease that, in a naturally occurring system, is activated by a single crRNA in the absence of a tracrRNA, wherein the Cas nuclease comprises a type V-A Cas nuclease, and
(c) the Cas nuclease;
thereby resulting in cleavage of the target DNA.
21 . The method of claim 20 wherein the contacting occurs in vitro.
22 . The method of claim 20 wherein the contacting occurs in a cell ex vivo.
23 . The method of claim 22 wherein the target DNA is genomic DNA of the cell.
24 . The method of claim 22 wherein the system is delivered into the cell as a pre-formed RNP complex.
25 . The method of claim 24 wherein the pre-formed RNP complex is delivered into the cell by electroporation.
26 . A method of editing a genome of a eukaryotic cell, the method comprising delivering an engineered, non-naturally occurring system comprising
(a) a targeter nucleic acid comprising, from 5′ to 3′:
(i) a targeter stem sequence; and
(ii) a spacer sequence designed to hybridize with a target nucleotide sequence within the genome; and
(b) a modulator nucleic acid comprising a modulator stem sequence complementary to the targeter stem sequence,
wherein the targeter nucleic acid and the modulator nucleic acid are separate nucleic acids, wherein a loop structure between the modulator stem sequence and the targeter stem sequence is absent, and wherein a complex comprising the targeter nucleic acid and the modulator nucleic acid is capable of activating a CRISPR Associated (Cas) nuclease that, in a naturally occurring system, is activated by a single crRNA in the absence of a tracrRNA, wherein the Cas nuclease comprises a type V-A Cas nuclease, and
(c) the Cas nuclease; and/or a polynucleotide or polynucleotides coding for one or more of (a), (b), and/or (c),
into the eukaryotic cell, thereby resulting in editing of the genome of the eukaryotic cell.
27 . The method of claim 26 , wherein the system is delivered into the cell as a pre-formed RNP complex.
28 . The method of claim 27 wherein the system is delivered into the cell by electroporation.
29 . The method of claim 26 wherein the cell is an immune cell or a stem cell.
30 . The method of claim 29 wherein the cell is an immune cell that is a T lymphocyte.